- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.09. | ELICERA THERAPEUTICS: Elicera clarifies status of the iTANK-platform patent application in the U.S. | 1 | Cision News | ||
| 19.09. | Elicera Therapeutics AB: Elicera clarifies status of the iTANK-platform patent application in the U.S. | 106 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 29.08. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 30 June 2025 | 128 | GlobeNewswire (Europe) | Second quarter (April-June 2025)
Operating loss amounted to SEK -2,892,341 (-5,841,409).
Loss for the period amounted to SEK -2,732,070 (-5,622,779).
Cash flow from operating activities totaled... ► Artikel lesen | |
| 25.08. | ELICERA THERAPEUTICS: Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy | 2 | Cision News | ||
| 25.08. | Elicera Therapeutics AB: Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy | 103 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 25.08. | Elicera Therapeutics AB: Elicera Therapeutics Continues Phase I/IIa CARMA Study with CAR T-Cell Therapy as Planned Following Safety Committee's Assessment in Cohort 2 | 110 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 28.05. | Elicera Therapeutics AB: Elicera Therapeutics enters a Material Transfer Agreement with University Hospital Tübingen for testing of the company's oncolytic virus candidates, ELC-100 and ELC-201 | 148 | GlobeNewswire (Europe) | Gothenburg, May 28, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology... ► Artikel lesen | |
| 22.05. | Elicera Therapeutics AB: Elicera reports: Active lymphoma eliminated in two out of three patients in the first cohort of the CARMA study with iTANK-armed CAR T-cell therapy | 142 | GlobeNewswire (Europe) | Gothenburg, May 22, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.05. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 31 March 2025 | 152 | GlobeNewswire (Europe) | First quarter (January-March 2025)
Operating loss amounted to SEK -8,069,404 (-5,433,422).
Loss for the period amounted to SEK -8,013,462 (-5,369,677).
Cash flow from operating activities totalled... ► Artikel lesen | |
| 14.04. | ELICERA THERAPEUTICS: Green light to continue Elicera's CARMA-trial in B-cell lymphoma | 2 | Cision News | ||
| 10.04. | Elicera Therapeutics AB: Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee's assessment of cohort 1 | 286 | GlobeNewswire (Europe) | Gothenburg, April 10, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 26.02. | Elicera Therapeutics - Positioned to deliver in cell and gene therapies | 364 | Edison Investment Research | Elicera Therapeutics is a cell and gene therapy company utilising its iTANK platform to develop immunotherapies for solid and bloodborne tumours. Its pipeline comprises two CAR-T therapies and two oncolytic... ► Artikel lesen | |
| 03.02. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Year-end Report 1 January - 31 December 2024 | 156 | GlobeNewswire (Europe) | Fourth quarter (October-December 2024)
Operating profit/loss amounted to SEK -2,911,958 (-5,212,694).
Loss for the period amounted to SEK -2,603,242 (-4,749,222).
Cash flow from operating activities... ► Artikel lesen | |
| 28.11.24 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 September 2024 | 116 | GlobeNewswire (Europe) | Third quarter (July-September 2024)
Operating profit/loss amounted to SEK -2,697,267 (-5,149,440).
Loss for the period amounted to SEK -2,514,629 (-5,046,574).
Cash flow from operating activities... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,744 | +2,00 % | Rheinmetall Aktie: Große Chance? - ABO Energy, Evotec, Funkwerk, MPC Capital und Redcare Pharmacy im Marktbericht Börse Frankfur | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 516,40 | +0,12 % | Formycon erzielt Vergleich mit Regeneron - US-Start für FYB203 | Formycon hat mit Regeneron eine Vergleichs- und Lizenzvereinbarung zu seinem Aflibercept-Biosimilar FYB203/AHZANTIVE geschlossen. Damit werden sämtliche Patentstreitigkeiten vor dem US-Bezirksgericht... ► Artikel lesen | |
| BRAIN BIOTECH | 2,290 | +1,78 % | EQS-PVR: BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: BRAIN Biotech AG
BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
02.10.2025 / 09:00 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,910 | +0,33 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,410 | +7,63 % | Burcon NutraScience Corporation: Burcon Announces New Board Members and Results of Shareholder Meeting | Vancouver, British Columbia--(Newsfile Corp. - September 17, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) (the "Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| CSL | 117,28 | +0,67 % | CSL LIMITED: Update - Notification of buy-back - CSL | ||
| MANNKIND | 4,950 | +0,06 % | MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer | WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 10,055 | +9,10 % | Studienoptimismus: Piper Sandler hebt Kursziel für Ocular Therapeutix auf 31 US-Dollar an | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,804 | +0,56 % | Oxford Nanopore Tech - Issue of Equity and Total Voting Rights | ||
| ADAPTIMMUNE THERAPEUTICS | 0,116 | -0,85 % | Adaptimmune Therapeutics PLC: Adaptimmune Reports Q2 Financial Results and Provides Business Update | Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to... ► Artikel lesen | |
| CODEXIS | 2,122 | -0,28 % | Benchmark reiterates Hold rating on Codexis stock after Q2 results | ||
| TELO GENOMICS | 0,036 | -19,10 % | Telo Genomics Corp.: Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update | Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for... ► Artikel lesen | |
| CORMEDIX | 9,500 | +1,06 % | CorMedix, Inc.: CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO | - Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allogeneic Blood and Marrow Transplant - - Topline Results from ReSPECT Study... ► Artikel lesen | |
| BIORA THERAPEUTICS | 0,001 | -100,00 % | NSE - BIORA THERAPEUTICS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities |
Das Unternehmen ELICERA THERAPEUTICS AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,705 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.